CNMD logo

CONMED CORP

CNMDNYSE
πŸ† #2177 by market capEarnings Feb 3US Equity
$45.25β–Ό $0.52 (βˆ’1.13%)
Latest quote
πŸ””
Track CNMD
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.1%
7dβ–Ό 8.2%
14dβ–Ό 4.0%
30dβ–Ό 3.0%
ytdβ–² 11.4%
1yβ–Ό 3.1%
🏦Market Cap
$1.36B
Small Cap
πŸ“ˆRevenue Growth (YoY)
5.2%
Slowing
πŸ“ŠGross Margin
57.2%
Healthy
πŸ’΅FCF Margin
9.7%
Moderate
βš–οΈP/S Ratio
1.0x
Cheap
Otter Score
76
Strong

Trading Snapshot

Day Range
$43.50 – $46.09
52-Week Range
$31.44 – $53.66
Volume (shares)
157,196
Avg Volume (shares)
β€”
Shares Outstanding
30.0M
Next Earnings
2027-02-03

Fundamentals Snapshot

Annual Revenue
$1.37B
Last Q Revenue
$343M
P/E Ratio
18.7
P/S Ratio
1.0x
EPS (TTM)
$2.45
Dividend Yield
0.00%
Dilution (1yr)
βˆ’0.3%
CNMD logo

CONMED CORP

CNMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.4Bβ–² +5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%β–Ό βˆ’5.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$141Mβ–Ό βˆ’29.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$151Mβ–Ό βˆ’2.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.0Mβ–Ό βˆ’0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$794Mβ–² +$87M YoY
StockOtter Β· stockotter.space

About CONMED CORP

CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

MarketBeatΒ·13h ago

CONMED Q3 Earnings Call Highlights

CONMED NYSE: CNMD reported third-quarter 2026 revenue of $335.6 million, with organic constant-currency sales growth of 6.7% as the medical technology company cited broad-based contributions from its general surgery and

Seeking AlphaΒ·14h ago

CONMED Corporation (CNMD) Q3 2026 Earnings Call Transcript

CONMED Corporation ( CNMD ) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDT Company Participants Patrick Beyer - President, CEO & Director John Gallagher - Executive VP, CFO and Principal Financial & Accounting Office

Zacks Investment ResearchΒ·20h ago

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $1.08 per share a year ago.

Zacks Investment ResearchΒ·21h ago

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est

Business WireΒ·1d ago

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarte

GuruFocusΒ·22d ago

Is Conmed Corp (CNMD) a Bargain After 6.0% Drop? GF Value Says Undervalued

On October 06, 2026, Conmed Corp (CNMD) shares fell 6.0% to a current price of $44.48, marking a significant decline in the context of a 52-week range of $31.44